Fatigue in primary biliary cirrhosis

Nature Reviews Gastroenterology and Hepatology

Volumn 7, Issue 6, 2010, Pages 313-319

  Abbas, Ghulam ^a   Jorgensen, Roberta A ^a   Lindor, Keith D ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; ADIPOCYTOKINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; COLCHICINE; CYCLOSPORIN; CYTOKINE; FLUVOXAMINE; ISOPREGNANOLONE; METHIONINE; METHOTREXATE; MODAFINIL; NALMEFENE; ONDANSETRON; PLACEBO; PRASTERONE SULFATE; PROGESTERONE; PROGESTERONE DERIVATIVE; RETINOL; SELENIUM; UBIQUINONE; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; BENZHYDRYL DERIVATIVE;

ANEMIA; AUTONOMIC NEUROPATHY; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; CYTOKINE PRODUCTION; DAYTIME SOMNOLENCE; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG TREATMENT FAILURE; EMOTIONAL STRESS; FATIGUE; FATIGUE IMPACT SCALE; FATIGUE SEVERITY SCALE; FIBROMYALGIA; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY DYSFUNCTION; LIVER FAILURE; LIVER FIBROSIS; MUSCLE DISEASE; NONHUMAN; PATHOGENESIS; PBC 40; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PRURITUS; RATING SCALE; REVIEW; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SHORT FORM 36; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT RESPONSE; ANIMAL; AUTONOMIC NERVOUS SYSTEM; COMPLICATION; HEALTH STATUS INDICATOR; IMMUNOLOGY; LIVER CIRRHOSIS, BILIARY; LIVER TRANSPLANTATION; METABOLISM; PATHOPHYSIOLOGY; SKELETAL MUSCLE;

ADIPOKINES; ANIMALS; AUTONOMIC NERVOUS SYSTEM; BENZHYDRYL COMPOUNDS; CYTOKINES; DIAGNOSIS, DIFFERENTIAL; FATIGUE; HEALTH STATUS INDICATORS; HUMANS; LIVER CIRRHOSIS, BILIARY; LIVER TRANSPLANTATION; MUSCLE, SKELETAL; PROGESTERONE;

EID: 77953291172     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2010.62     Document Type: Review

References (80)

1. Kim, W. R. et al. epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 119, 1631-1636 (2000).
2. Kaplan, M. M. & Gershwin, M. e. Primary biliary cirrhosis. N. Engl. J. Med. 353, 1261-1273 (2005).
3. Lee, Y. M. & Kaplan, M. M. The natural history of PBC: has it changed? Semin. Liver Dis. 25, 321-326 (2005).
4. Corpechot, C. et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 128, 297-303 (2005).
5. Kuiper, e. M. et al. improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 136, 1281-1287 (2009).
6. Huet, P. M., Deslauriers, J., Tran, A., Faucher, C. & Charbonneau, J. impact of fatigue on the quality of life of patients with primary biliary cirrhosis. Am. J. Gastroenterol. 95, 760-767 (2000).
7. Bergasa, N. v. The pruritus of cholestasis. J. Hepatol. 43, 1078-1088 (2005).
8. Cauch-Dudek, K., Abbey, S., Stewart, D. e. & Heathcote, e. J. Fatigue in primary biliary cirrhosis. Gut 43, 705-710 (1998).
9. Miller, e. R., Hiller, J. e. & Shaw, D. R. Quality of life in HCv-infection: lack of association with ALT levels. Aust. N. Z. J. Public Health 25, 355-361 (2001).
10. Jones, e. A. Fatigue associated with chronic liver disease: a riddle wrapped in a mystery inside an enigma. Hepatology 22, 1606-1608 (1995).
11. Fisk, J. D. et al. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin. Infect. Dis. 18 (Suppl. 1), S79-S83 (1994).
12. Jacoby, A. et al. Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis. Gut 54, 1622-1629 (2005).
13. Pares, A. & Rodes, J. Natural history of primary biliary cirrhosis. Clin. Liver Dis. 7, 779-794 (2003).
14. Prince, M. i., Chetwynd, A., Craig, W. L., Metcalf, J. v. & James, O. F. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut 53, 865-870 (2004).
15. Prince, M., Chetwynd, A., Newman, W., Metcalf, J. v. & James, O. F. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 123, 1044-1051 (2002).
16. Prince, M. i. & Jones, D. e. Primary biliary cirrhosis: new perspectives in diagnosis and treatment. Postgrad. Med. J. 76, 199-206 (2000).
17. Fahey, S. The experience of women with primary biliary cirrhosis: a literature review. J. Adv. Nurs. 30, 506-512 (1999).
18. Newton, J. L., Gibson, G. J., Tomlinson, M., Wilton, K. & Jones, D. Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence. Hepatology 44, 91-98 (2006).
19. Newton, J. L. et al. Population prevalence and symptom associations of autonomic dysfunction in primary biliary cirrhosis. Hepatology 45, 1496-1505 (2007).
20. Johns, M. W. Sleepiness in different situations measured by the epworth Sleepiness Scale. Sleep 17, 703-710 (1994).
21. Schrezenmaier, C. et al. evaluation of orthostatic hypotension: relationship of a new self-report instrument to laboratory-based measures. Mayo Clin. Proc. 80, 330-334 (2005).
22. Jones, D. e., Gray, J. C. & Newton, J. Perceived fatigue is comparable between different disease groups. QJM 102, 617-624 (2009).
23. Jones, D. e. et al. Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort. Gut 55, 536-541 (2006).
24. Krupp, L. B., LaRocca, N. G., Muir-Nash, J. & Steinberg, A. D. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch. Neurol. 46, 1121-1123 (1989).
25. Ware, J. e. Jr. SF-36 health survey update. Spine (Phila. Pa. 1796) 25, 3130-3139 (2000).
26. Kleinman, L. et al. Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C. Qual. Life Res. 9, 499-508 (2000).
27. Jones, e. A. & Yurdaydin, C. is fatigue associated with cholestasis mediated by altered central neurotransmission? Hepatology 25, 492-494 (1997).
28. Bergasa, N. v. & Jones, e. A. The pruritus of cholestasis: potential pathogenic and therapeutic implications of opioids. Gastroenterology 108, 1582-1588 (1995).
29. Jones, e. A. & Bergasa, N. v. The pruritus of cholestasis: from bile acids to opiate agonists. Hepatology 11, 884-887 (1990).
30. Thornton, J. R. & Losowsky, M. S. Opioid peptides and primary biliary cirrhosis. BMJ 297, 1501-1504 (1988).
31. Burak, K. W., Le, T. & Swain, M. G. increased sensitivity to the locomotor-activating effects of corticotropin-releasing hormone in cholestatic rats. Gastroenterology 122, 681-688 (2002).
32. Rose, C. et al. Manganese deposition in basal ganglia structures results from both portalsystemic shunting and liver dysfunction. Gastroenterology 117, 640-644 (1999).
33. Krieger, D. et al. Manganese and chronic hepatic encephalopathy. Lancet 346, 270-274 (1995).
34. Forton, D. M. et al. Fatigue and primary biliary cirrhosis: association of globus pallidus magnetisation transfer ratio measurements with fatigue severity and blood manganese levels. Gut 53, 587-592 (2004).
35. Hajnal, J. v. et al. Design and implementation of magnetization transfer pulse sequences for clinical use. J. Comput. Assist. Tomogr. 16, 7-18 (1992).
36. Newton, J. L. et al. Cognitive impairment in primary biliary cirrhosis: symptom impact and potential etiology. Hepatology 48, 541-549 (2008).
37. Garde, e., Lykke Mortensen, e., Rostrup, e. & Paulson, O. B. Decline in intelligence is associated with progression in white matter hyperintensity volume. J. Neurol. Neurosurg. Psychiatry 76, 1289-1291 (2005).
38. Newton, J. L. et al. Autonomic dysfunction in primary biliary cirrhosis correlates with fatigue severity. Eur. J. Gastroenterol. Hepatol. 19, 125-132 (2007).
39. Newton, J. L., Allen, J., Kerr, S. & Jones, D. e. Reduced heart rate variability and barolex sensitivity in primary biliary cirrhosis. Liver Int. 26, 197-202 (2006).
40. Mastorakos, G., Chrousos, G. P. & Weber, J. S. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J. Clin. Endocrinol. Metab. 77, 1690-1694 (1993).
41. vgontzas, A. N. et al. elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J. Clin. Endocrinol. Metab. 82, 1313-1316 (1997).
42. Swain, M. G. & Maric, M. improvement in cholestasis-associated fatigue with a serotonin receptor agonist using a novel rat model of fatigue assessment. Hepatology 25, 291-294 (1997).
43. Nagano, T. et al. Cytokine profile in the liver of primary biliary cirrhosis. J. Clin. Immunol. 19, 422-427 (1999).
44. Martinez, O. M., villanueva, J. C., Gershwin, M. e. & Krams, S. M. Cytokine patterns and cytotoxic mediators in primary biliary cirrhosis. Hepatology 21, 113-119 (1995).
45. Bautmans, i., Njemini, R., Lambert, M., Demanet, C. & Mets, T. Circulating acute phase mediators and skeletal muscle performance in hospitalized geriatric patients. J. Gerontol. A Biol. Sci. Med. Sci. 60, 361-367 (2005).
46. Breidert, M., Zimmermann, T. F., Schneider, R., ehninger, G. & Brabant, G. Ghrelin/leptinimbalance in patients with primary biliary cirrhosis. Exp. Clin. Endocrinol. Diabetes 112, 123-126 (2004).
47. Piche, T. et al. Fatigue is associated with high circulating leptin levels in chronic hepatitis C. Gut 51, 434-439 (2002).
48. Sakurai, T. Roles of orexin/hypocretin in regulation of sleep/wakefulness and energy homeostasis. Sleep Med. Rev. 9, 231-241 (2005).
49. Hosoi, T., Kawagishi, T., Okuma, Y., Tanaka, J. & Nomura, Y. Brain stem is a direct target for leptin's action in the central nervous system. Endocrinology 143, 3498-3504 (2002).
50. Ahboucha, S. et al. Neuroactive steroids and fatigue severity in patients with primary biliary cirrhosis and hepatitis C. Neurogastroenterol. Motil. 20, 671-679 (2008).
51. Soderpalm, A. H., Lindsey, S., Purdy, R. H., Hauger, R. & Wit de, H. Administration of progesterone produces mild sedative-like effects in men and women. Psychoneuroendocrinology 29, 339-354 (2004).
52. Freeman, e. W., Purdy, R. H., Coutifaris, C., Rickels, K. & Paul, S. M. Anxiolytic metabolites of progesterone: correlation with mood and performance measures following oral progesterone administration to healthy female volunteers. Neuroendocrinology 58, 478-484 (1993).
53. Sundstrom, i. & Backstrom, T. Patients with premenstrual syndrome have decreased saccadic eye velocity compared to control subjects. Biol. Psychiatry 44, 755-764 (1998).
54. Paul, S. M. & Purdy, R. H. Neuroactive steroids. FASEB J. 6, 2311-2322 (1992).
55. Wang, M. D., Backstrom, T. & Landgren, S. The inhibitory effects of allopregnanolone and pregnanolone on the population spike, evoked in the rat hippocampal CA1 stratum pyramidale in vitro, can be blocked selectively by epiallopregnanolone. Acta Physiol. Scand. 169, 333-341 (2000).
56. Hommer, D. W. et al. Benzodiazepine sensitivity in normal human subjects. Arch. Gen. Psychiatry 43, 542-551 (1986).
57. Goldblatt, J. et al. The true impact of fatigue in primary biliary cirrhosis: a population study. Gastroenterology 122, 1235-1241 (2002).
58. Blackburn, P., Freeston, M., Baker, C. R., Jones, D. e. & Newton, J. L. The role of psychological factors in the fatigue of primary biliary cirrhosis. Liver Int. 27, 654-661 (2007).
59. Jones, D. e. Fatigue in cholestatic liver disease: is it all in the mind? J. Hepatol. 46, 992-994 (2007).
60. van Os, e. et al. Depression in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J. Hepatol. 46, 1099-1103 (2007).
61. Goldblatt, J., James, O. F. & Jones, D. e. Grip strength and subjective fatigue in patients with primary biliary cirrhosis. JAMA 285, 2196-2197 (2001).
62. Newton, J. L., Bhala, N., Burt, J. & Jones, D. e. Characterisation of the associations and impact of symptoms in primary biliary cirrhosis using a disease specific quality of life measure. J. Hepatol. 44, 776-783 (2006).
63. Amann, M. & Dempsey, J. A. Locomotor muscle fatigue modifies central motor drive in healthy humans and imposes a limitation to exercise performance. J. Physiol. 586, 161-173 (2008).
64. Hollingsworth, K. G. et al. Pilot study of peripheral muscle function in primary biliary cirrhosis: potential implications for fatigue pathogenesis. Clin. Gastroenterol. Hepatol. 6, 1041-1048 (2008).
65. Swain, M. G. & Le, T. Chronic cholestasis in rats induces anhedonia and a loss of social interest. Hepatology 28, 6-10 (1998).
66. Burak, K. W., Le, T. & Swain, M. G. increased midbrain 5-HT1A receptor number and responsiveness in cholestatic rats. Brain Res. 892, 376-379 (2001).
67. Butterworth, R. F. et al. Dehydroepiandrosterone sulphate improves cholestasis-associated fatigue in bile duct ligated rats. Neurogastroenterol. Motil. 21, 1319-1325 (2009).
68. Ahboucha, S. et al. Reduced plasma dehydroepiandrosterone sulfate levels are significantly correlated with fatigue severity in patients with primary biliary cirrhosis. Neurochem. Int. 52, 569-574 (2008).
69. Prince, M. i. et al. Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multicentre, randomized, placebo-controlled, cross-over trial. Aliment. Pharmacol. Ther. 17, 137-143 (2003).
70. ter Borg, P. C., van Os, e., van den Broek, W. W., Hansen, B. e. & van Buuren, H. R. Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [iSRCTN88246634]. BMC Gastroenterol. 4, 13 (2004).
71. Talwalkar, J. A. et al. Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial. Dig. Dis. Sci. 51, 1985-1991 (2006).
72. Theal, J. J. et al. A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue. Hepatology 41, 1305-1312 (2005).
73. Battezzati, P. M. et al. Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients. Aliment. Pharmacol. Ther. 15, 1427-1434 (2001).
74. ian Gan, S., de Jongh, M. & Kaplan, M. M. Modafinil in the treatment of debilitating fatigue in primary biliary cirrhosis: a clinical experience. Dig. Dis. Sci. 54, 2242-2246 (2009).
75. Babatin, M. A., Sanai, F. M. & Swain, M. G. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy. Aliment. Pharmacol. Ther. 24, 813-820 (2006).
76. Wiesner, R. H. et al. A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N. Engl. J. Med. 322, 1419-1424 (1990).
77. Jones, D. e. & Newton, J. L. An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis. Aliment. Pharmacol. Ther. 25, 471-476 (2007).
78. elta, G. H. et al. increased incidence of hypothyroidism in primary biliary cirrhosis. Dig. Dis. Sci. 28, 971-975 (1983).
79. Bergasa, N. v. et al. Primary biliary cirrhosis: report of a focus study group. Hepatology 40, 1013-1020 (2004).
80. Bjornsson, e. et al. Fatigue measurements in patients with primary biliary cirrhosis and the risk of mortality during follow-up. Liver Int. doi:10.1111/j.1478-3231.2009.02160.x..